Morgan Stanley Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Key Points

• Morgan Stanley has lowered its price target for Regeneron Pharmaceuticals from $761.00 to $756.00, maintaining an "overweight" rating, which suggests potential upside from the current stock price.
• Despite the drop in price target, Regeneron has seen mixed ratings from other analysts, with some maintaining "buy" ratings and target prices up to $890.00.
• In recent trading, Regeneron Pharmaceuticals stock was down by 1.5%, closing at $561.16, with a significant trading volume of 486,636 shares during the session.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price target dropped by research analysts at Morgan Stanley from $761.00 to $756.00 in a report released on Friday,Benzinga reports. The firm currently has an "overweight" rating on the biopharmaceutical company's stock. Morgan Stanley's price objective points to a potential upside of 34.72% from the stock's current price.

REGN has been the topic of a number of other reports. Canaccord Genuity Group reissued a "buy" rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective on the stock. in a research note on Friday, August 1st. Rothschild & Co Redburn began coverage on Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a "buy" rating and a $890.00 target price on the stock. Royal Bank Of Canada increased their target price on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a research note on Monday, August 4th. Finally, Argus lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $817.46.

Regeneron Pharmaceuticals Stock Down 1.5%

NASDAQ REGN traded down $8.74 during trading hours on Friday, hitting $561.16. 486,636 shares of the company traded hands, compared to its average volume of 1,100,869. Regeneron Pharmaceuticals has a twelve month low of $476.49 and a twelve month high of $1,024.36. The stock has a market capitalization of $59.48 billion, a price-to-earnings ratio of 14.27, a P/E/G ratio of 1.81 and a beta of 0.31. The business's 50-day moving average is $573.83 and its 200-day moving average is $565.52. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the company earned $11.56 EPS. The company's revenue was up 3.6% on a year-over-year basis. Sell-side analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. E Fund Management Hong Kong Co. Ltd. boosted its holdings in shares of Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. Activest Wealth Management grew its position in shares of Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 21 shares during the last quarter. Costello Asset Management INC bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth about $27,000. Saudi Central Bank bought a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $27,000. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Regeneron Pharmaceuticals during the second quarter valued at approximately $31,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.